Viruses Within the Flaviviridae Decrease CD4 Expression and Inhibit HIV Replication in Human CD4+ Cells
Overview
Authors
Affiliations
Viral infections alter host cell homeostasis and this may lead to immune evasion and/or interfere with the replication of other microbes in coinfected hosts. Two flaviviruses are associated with a reduction in HIV replication or improved survival in HIV-infected people (dengue virus (DV) and GB virus type C (GBV-C)). GBV-C infection and expression of the GBV-C nonstructural protein 5A (NS5A) and the DV NS5 protein in CD4(+) T cells inhibit HIV replication in vitro. To determine whether the inhibitory effect on HIV replication is conserved among other flaviviruses and to characterize mechanism(s) of HIV inhibition, the NS5 proteins of GBV-C, DV, hepatitis C virus, West Nile virus, and yellow fever virus (YFV; vaccine strain 17D) were expressed in CD4(+) T cells. All NS5 proteins inhibited HIV replication. This correlated with decreased steady-state CD4 mRNA levels and reduced cell surface CD4 protein expression. Infection of CD4(+) T cells and macrophages with YFV (17D vaccine strain) also inhibited HIV replication and decreased CD4 gene expression. In contrast, mumps virus was not inhibited by the expression of flavivirus NS5 protein or by YFV infection, and mumps infection did not alter CD4 mRNA or protein levels. In summary, CD4 gene expression is decreased by all human flavivirus NS5 proteins studied. CD4 regulation by flaviviruses may interfere with innate and adaptive immunity and contribute to in vitro HIV replication inhibition. Characterization of the mechanisms by which flaviviruses regulate CD4 expression may lead to novel therapeutic strategies for HIV and immunological diseases.
Nedumpun T, Rungprasert K, Ninvilai P, Limcharoen B, Tunterak W, Prakairungnamthip D Poult Sci. 2024; 104(2):104731.
PMID: 39740493 PMC: 11750524. DOI: 10.1016/j.psj.2024.104731.
Co-Infections and Superinfections between HIV-1 and Other Human Viruses at the Cellular Level.
Acchioni C, Sandini S, Acchioni M, Sgarbanti M Pathogens. 2024; 13(5).
PMID: 38787201 PMC: 11124504. DOI: 10.3390/pathogens13050349.
Characterization of "Off-Target" Immune Modulation Induced by Live Attenuated Yellow Fever Vaccine.
Xiang J, Chang Q, McLinden J, Bhattarai N, Welch J, Kaufman T J Infect Dis. 2023; 229(3):786-794.
PMID: 36994927 PMC: 10938199. DOI: 10.1093/infdis/jiad086.
Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.
Samadi M, Salimi V, Haghshenas M, Miri S, Mohebbi S, Ghaemi A Virol J. 2022; 19(1):41.
PMID: 35264187 PMC: 8905790. DOI: 10.1186/s12985-022-01769-3.
The Present and Future of Yellow Fever Vaccines.
Hansen C, Barrett A Pharmaceuticals (Basel). 2021; 14(9).
PMID: 34577591 PMC: 8468696. DOI: 10.3390/ph14090891.